Re-Restenosis and Target Lesion Revascularization After Treatment of Sirolimus-Eluting Stent Restenosis Retrospective Analysis From 4 Japanese Hospitals
| Autor: | Toshiharu Himi, Akira Miyazaki, Yoshihide Fujimoto, Seiichi Haruta, Yoshitake Nakamura, Hideo Takebayashi, Hideki Kitahara, Yoshio Kobayashi, Issei Komuro, Nakabumi Kuroda |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Stent General Medicine Balloon medicine.disease Revascularization Lesion Coronary artery disease Restenosis Sirolimus Internal medicine Angioplasty medicine Cardiology medicine.symptom Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Circulation Journal. 73:867-871 |
| ISSN: | 1347-4820 1346-9843 |
| DOI: | 10.1253/circj.cj-08-0851 |
| Popis: | Background: There is limited information about optimal management of drug-eluting stent (DES) restenosis. This study evaluated the incidences of re-restenosis and re-target lesion revascularization (TLR) after the treatment of sirolimus-eluting stent (SES) restenosis. Methods and Results: A total of 102 lesions in 101 patients who underwent TLR for SES restenosis were classified according to: (1) focal (lesion length ≤10 mm) or non-focal restenosis (>10 mm); and (2) use of DES for TLR: (1) focal restenosis treated with DES (focal-DES, n=40); (2) focal restenosis treated by balloon angioplasty (focal-balloon, n=31); (3) non-focal restenosis with DES (non-focal-DES, n=17); and (4) non-focal restenosis by balloon angioplasty (non-focal-balloon, n=14). Re-restenosis and re-TLR were observed in 6 (19.4%) and 5 lesions (12.5%) of the focal-DES group, in 13 (65.0%) and 11 (35.5%) of the focal-balloon group, in 7 (50.0%) and 6 (35.3%) of the non-focal-DES group, and in 8 (61.5%) and 7 (50.0%) of the non-focal-balloon group, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|